PF-07934040 — Investigational Agent
KRAS Inhibitor · Phase 1 · Pfizer
Mechanism of Action
Orally bioavailable small-molecule inhibitor targeting non-G12C KRAS driver mutations (including KRAS G12V and G12A), locking the oncogenic GTPase in an inactive state to shut down downstream MAPK signaling. Designed to broaden actionable KRAS coverage beyond G12C in NSCLC and other solid tumors.
Investigational Indications
- KRAS-mutant non-small cell lung cancer
- KRAS-mutant advanced solid tumors